CML Publications from the Middle East

• ABL kinase domain mutations in Iranian chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors
  Shojaei M et al. Lab Med, March 2021
• ABL kinase domain mutations in Iranian chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors
  Shojaei M et al. Lab Med, August 2020 (epub ahead of print)
• Evaluation of molecular response to imatinib mesylate treatment in Iranian patients with chronic myeloid leukemia
  Nekoohesh L et al. Clin Lymphoma Myeloma Leuk, January 2020
• Myeloid leukemias: A glance at Middle Eastern Centers
  Khaled SA et al. J Blood Med, December 2019 – open access publications
• Signaling pathways involved in chronic myeloid leukemia pathogenesis: The importance of targeting Musashi2-Numb signaling to eradicate leukemia stem cells
  Moradi F et al. Iran Basic Med Sci, June 2019

• Association of BCR-ABL transcript variants with different blood parameters and demographic features in Iraqi chronic myeloid leukemia patients
  Khazaal MS et al. Mol Genet Genomic Med, June 2019 (epub ahead of print)
• Tendency of K562 chronic myeloid leukemia cells toward cell reprogramming
  Yilmazer Aktuna A et al. Turk J Haematol, May 2018
  (epub ahead of print)
• Additional cytogenetic aberrations in chronic myeloid leukemia: a single-center experience in the Middle East
  Safaei A et al. Blood Res, April 2018
• BCR-ABL fusion genes and laboratory findings in patients with chronic myeloid leukemia in northeast Iran
  Ayatollahi H et al. Caspian J Intern Med, 2018
• ASX1 and JAK2V617F gene mutation screening in Iranian patients with chronic myeloid leukemia
  Valikhani A et al. Asia Pac J Clin Oncol, April 2017
• Allogeneic transplantation in chronic myeloid leukemia and the effect of tyrosine kinase inhibitors on survival: A quasi-experimental study
  Özen M et al. Turk J Haematol, March 2017
• Consistency test between scoring systems for predicting outcomes of chronic myeloid leukemia in a Saudi population treated with imatinib
  Banjar HR et al. Int Sch Res Notices, February 2017
• Hodgkin lymphoma in a case of chronic myeloid leukemia treated with tyrosine kinase inhibitors
  Gajandra S et al. Turk Patoloji Derg, February 2017